Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 715-718, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, Y.-Y.
Right arrow Articles by Csako, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, Y.-Y.
Right arrow Articles by Csako, G.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2000;46:715-718.)
© 2000 American Association for Clinical Chemistry, Inc.

Technical Briefs

Semiautomated PCR-Single-Strand Conformation Polymorphism Method for Detection of a Novel Sequence Polymorphism (Ile1000Val) in Human {alpha}2-Macroglobulin

Yan-Yun Wu1, Rosario M. Delgado1, Trey Sunderland2 and Gyorgy Csako1,a

1 Clinical Pathology Department, Warren G. Magnuson Clinical Center

2 Geriatric Psychiatry Branch, National Institute of Mental Health, NIH, Bethesda, MD 20892
a address correspondence to this author at: Clinical Pathology Department, NIH, Bldg. 10, Rm. 2C-407, Bethesda, MD 20892-1508

{alpha}2-Macroglobulin ({alpha}2M) biochemically is a glycoprotein, structurally is a tetramer of identical subunits (182 000 Da each), and functionally is a major human plasma pan-proteinase inhibitor (1). Its gene (A2M) has been mapped to chromosome 12p12-13 (2). Investigations into the pathogenesis of Alzheimer disease (AD) revealed that {alpha}2M is associated with senile plaques (3), binds to Aß peptide, the major component of ß-amyloid (4); attenuates fibrillogenesis and neurotoxicity of Aß (4)(5); and mediates Aß degradation (6)(7). Activated {alpha}2M, apolipoprotein E-enriched lipoproteins, and amyloid precursor protein share the same neuronal cell surface receptor, LDL receptor-related protein ({alpha}2M-r/LRP) (3)(7). Consequently, there has been a growing interest in exploring possible associations between alterations of the A2M gene and AD risk. Two A2M polymorphisms, both involving functional domains, have been suggested to be related to AD risk (8)(9)(10)(11). One involves a pentanucleotide deletion adjacent to a consensus splice site in intron 17 (5' to exon 18) of A2M, and it may cause exon skipping (12). The other involves an A-to-G transition in exon 24, at position 1000 based on the cDNA sequence (13)(14) or at position 976 based on the mature protein (9), and it changes Ile (ATC) to Val (GTC) near the thiol ester site of {alpha}2M (9). The resulting polymorphism is of high frequency, with an allele distribution of 65–70% A and 30–35% G in Caucasian populations (13)(14)(15).

Current evidence for an A2M gene-AD risk connection is, however, conflicting. Several studies have failed to establish an association between AD and the . . . [Full Text of this Article]


Footnotes


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.